Literature DB >> 12462554

Early circulating lymphocyte apoptosis in human septic shock is associated with poor outcome.

Yves Le Tulzo1, Céllne Pangault, Arnaud Gacouin, Valérie Guilloux, Olivier Tribut, Laurence Amiot, Pierre Tattevin, Rémi Thomas, Renée Fauchet, Bernard Drénou.   

Abstract

The role of lymphocyte apoptosis in septic shock remains a controversial issue. Using Annexin V and flow cytometry analysis on freshly isolated cells, we evaluated circulating lymphocyte apoptosis in 23 septic shock, 25 sepsis without shock, 7 nonseptic critically ill, and 25 control patients. In patients with sepsis, we compared day 1 lymphocyte apoptosis (i.e., within 3 days of the onset of infection) with that observed 5-7 days after (day 6) according to shock state, mortality, and seventy factors. At day 1, patients in septic shock exhibited higher lymphocyte apoptosis than that present in controls (16.5% +/- 3.5% vs. 3% +/- 0.5%, respectively, P = 0.0001). At day 6, patients with sepsis without shock restored undamaged CD4+ T and CD8+ T lymphocyte counts, whereas patients in septic shock increased only CD4+ T cells. Similarly, survivors restored undamaged lymphocyte count at day 6 (+70%, P < 0.001), whereas nonsurvivors did not. Day 6 undamaged lymphocyte count negatively correlated with day 1 SAPS II, day 6 LOD score, mechanical ventilation, and ICU stay duration. We observed no apoptotic effect of septic shock plasma or septic shock circulating mononuclear cells on target lymphoid cell lines. We found no alteration in any death receptors Fas, TRAIL-R1, TRAIL-R2, or in their ligands on circulating blood cells. Catecholamines and interleukin 10 levels significantly increased in patients with septic shock, but did not correlate with apoptosis levels. We conclude that lymphocyte apoptosis is rapidly increased in blood of patients in septic shock and that lymphocyte apoptosis leads to a profound and persistent lymphopenia associated with poor outcome. These results suggest that lymphocyte apoptosis is one of the main components of human septic shock immune dysfunction and could be related more to microcirculatory disturbance than to circulating factors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12462554     DOI: 10.1097/00024382-200212000-00001

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  114 in total

Review 1.  Epigenetic regulation of immune cell functions during post-septic immunosuppression.

Authors:  William F Carson; Karen A Cavassani; Yali Dou; Steven L Kunkel
Journal:  Epigenetics       Date:  2011-03-01       Impact factor: 4.528

2.  The influence of G-CSF addition to antibiotic treatment of experimental sepsis on pulmonary tissue.

Authors:  Sevim Aydin; Rahmet Caylan; Kemalettin Aydin; Esin Yulug; Engin Yenilmez; Iftihar Koksal
Journal:  J Natl Med Assoc       Date:  2005-11       Impact factor: 1.798

3.  Apoptosis of lymphocytes in peripheral blood of patients with melanoma.

Authors:  Faruk Tas; Derya Duranyildiz; Andac Argon; Hilal Oguz; Hakan Camlica; Vildan Yasasever; Erkan Topuz
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

4.  High interleukin 12 and low interleukin 10 production after in vitro stimulation detected in sepsis survivors.

Authors:  Spaska A Stanilova; Zhivko T Karakolev; Gospodin S Dimov; Zlatka G Dobreva; Lyuba D Miteva; Emil S Slavov; Chavdar S Stefanov; Noyko S Stanilov
Journal:  Intensive Care Med       Date:  2005-02-18       Impact factor: 17.440

Review 5.  Anaphylatoxins: their role in bacterial infection and inflammation.

Authors:  Pieter-Jan Haas; Jos van Strijp
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

Review 6.  The compensatory anti-inflammatory response syndrome (CARS) in critically ill patients.

Authors:  Nicholas S Ward; Brian Casserly; Alfred Ayala
Journal:  Clin Chest Med       Date:  2008-12       Impact factor: 2.878

7.  Adoptive transfer of apoptotic splenocytes worsens survival, whereas adoptive transfer of necrotic splenocytes improves survival in sepsis.

Authors:  Richard S Hotchkiss; Katherine C Chang; Mitchell H Grayson; Kevin W Tinsley; Benjamin S Dunne; Christopher G Davis; Dale F Osborne; Irene E Karl
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-07       Impact factor: 11.205

8.  Immune status in sepsis: the bug, the site of infection and the severity can make the difference.

Authors:  Jean-Marc Cavaillon; Minou Adib-Conquy
Journal:  Crit Care       Date:  2010-06-18       Impact factor: 9.097

9.  Prevention of immune cell apoptosis as potential therapeutic strategy for severe infections.

Authors:  Janie Parrino; Richard S Hotchkiss; Mike Bray
Journal:  Emerg Infect Dis       Date:  2007-02       Impact factor: 6.883

10.  VX-166: a novel potent small molecule caspase inhibitor as a potential therapy for sepsis.

Authors:  Peter Weber; Ping Wang; Stephane Maddens; Paul Sh Wang; Rongqian Wu; Michael Miksa; Weifeng Dong; Michael Mortimore; Julian M C Golec; Peter Charlton
Journal:  Crit Care       Date:  2009-09-09       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.